The deal is the latest in Moderna’s push to expand beyond COVID as demand for the shots falls dramatically, and develop a vaccine for cancer, a dream that scientists have chased for decades with little success. Moderna is already developing a cancer vaccine with Merck, which was shown to cut the risk of recurrence or death by 44 per cent in patients with deadly skin cancer melanoma, in a mid-stage trial. It also has vaccines under development for flu and respiratory syncytial virus (RSV), among others., The deal is the latest in Moderna’s push to expand beyond COVID as demand for the shots falls dramatically, and develop a vaccine for cancer, a dream that scientists have chased for decades with little success. Moderna is already developing a cancer vaccine with Merck, which was shown to cut the risk of recurrence or death by 44 per cent in patients with deadly skin cancer melanoma, in a mid-stage trial. It also has vaccines under development for flu and respiratory syncytial virus (RSV), among others., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way